143 related articles for article (PubMed ID: 20655775)
1. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
2. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
Lao Z; Ding LW; Sun QY; Jia L; Yan B; Ng AY; Capinpin SM; Wang R; Ying L; Chng WJ; Koeffler HP; Koh WP; Yuan JM; Yang H; Goh YT; Grigoropoulos N
Clin Cancer Res; 2024 May; 30(10):2170-2180. PubMed ID: 38437679
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A; Bernard E; Micol JB
Bull Cancer; 2023 Nov; 110(11):1129-1140. PubMed ID: 37391357
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
Higgins A; Shah MV
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
[TBL] [Abstract][Full Text] [Related]
6. Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Williams J; Heppel NH; Britt-Compton B; Grimstead JW; Jones RE; Tauro S; Bowen DT; Knapper S; Groves M; Hills RK; Pepper C; Baird DM; Fegan C
Br J Haematol; 2017 Jul; 178(2):240-249. PubMed ID: 28486748
[TBL] [Abstract][Full Text] [Related]
7. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Vartholomatos G
Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic signature of ionizing radiation in therapy-related AML patients.
O'Brien G; Cecotka A; Manola KN; Pagoni MN; Polanska J; Badie C
Heliyon; 2024 Jan; 10(1):e23244. PubMed ID: 38163095
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
[TBL] [Abstract][Full Text] [Related]
10. Genome-Wide Association Analyses Identify Variants in
Wang J; Clay-Gilmour AI; Karaesmen E; Rizvi A; Zhu Q; Yan L; Preus L; Liu S; Wang Y; Griffiths E; Stram DO; Pooler L; Sheng X; Haiman C; Van Den Berg D; Webb A; Brock G; Spellman S; Pasquini M; McCarthy P; Allan J; Stölzel F; Onel K; Hahn T; Sucheston-Campbell LE
Front Genet; 2021; 12():554948. PubMed ID: 34220922
[TBL] [Abstract][Full Text] [Related]
11. Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia.
Ghasemi A; Rostami S; Chahardouli B; Alizad Ghandforosh N; Ghotaslou A; Nadali F
Int J Hematol Oncol Stem Cell Res; 2015 Jan; 9(1):15-21. PubMed ID: 25802696
[TBL] [Abstract][Full Text] [Related]
12. [NGS-based molecular genetics of leukemia-a powerful and decentralized approach].
Dintner S; Schmutz M; Sommer S; Langer A; Hirschbühl K; Claus R; Schmid C; Trepel M; Märkl B
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):155-159. PubMed ID: 37975919
[TBL] [Abstract][Full Text] [Related]
13. Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis.
Ghasemi B; Ahmadi J; Zaker F; Tabatabaei T; Kiani-Zadeh M; Kazemi A
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):52-60. PubMed ID: 38312186
[TBL] [Abstract][Full Text] [Related]
14. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.
Roman E; Smith A; Appleton S; Crouch S; Kelly R; Kinsey S; Cargo C; Patmore R
Cancer Epidemiol; 2016 Jun; 42():186-98. PubMed ID: 27090942
[TBL] [Abstract][Full Text] [Related]
15. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.
Kontandreopoulou CN; Kalopisis K; Viniou NA; Diamantopoulos P
Front Oncol; 2022; 12():989483. PubMed ID: 36338673
[TBL] [Abstract][Full Text] [Related]
16. Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options.
Ma J; Wang Y
Ann Med; 2024 Dec; 56(1):2329132. PubMed ID: 38608646
[TBL] [Abstract][Full Text] [Related]
17. CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics.
Swanson AJ; Rogowski VJ; Bishop JA; Walker DM; Roxas GM; Raimondi SL
PLoS One; 2024; 19(3):e0300477. PubMed ID: 38466706
[TBL] [Abstract][Full Text] [Related]
18. Double trouble: IRAK1/4 inhibitors in AML/MDS.
Uckelmann HJ; Klusmann JH
Blood; 2023 Sep; 142(11):945-946. PubMed ID: 37707874
[No Abstract] [Full Text] [Related]
19. Dissecting DNA hypermethylation in cancer.
Estécio MR; Issa JP
FEBS Lett; 2011 Jul; 585(13):2078-86. PubMed ID: 21146531
[TBL] [Abstract][Full Text] [Related]
20. Genetic pathways leading to therapy-related myeloid neoplasms.
Stoddart A; McNerney ME; Bartom E; Bergerson R; Young DJ; Qian Z; Wang J; Fernald AA; Davis EM; Larson RA; White KP; Le Beau MM
Mediterr J Hematol Infect Dis; 2011; 3(1):e2011019. PubMed ID: 21713073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
